Recursion Pharmaceuticals Inc logo

Recursion Pharmaceuticals Inc(RXRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.9
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for RXRX

11/16/2026: RXRX (1-star) is currently NOT-A-BUY. Pass it for now.

Recursion Pharmaceuticals is a clinical-stage TechBio stock leveraging artificial intelligence and automated biology to transform drug discovery. Its primary strengths lie in its massive proprietary biological datasets, advanced supercomputing infrastructure, and validation partnerships with major pharmaceutical leaders. The investment story centers on the long-term potential to outpace traditional drug discovery timelines through its integrated platform, though the company faces significant execution, valuation, and clinical trial risks given its lack of commercial product sales and ongoing net losses. The stock is best suited for growth-oriented investors with high risk tolerance willing to monitor clinical trial milestones and partnership developments over a multi-year horizon.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitRecursion offers exposure to the high-growth intersection of artificial intelligence and biotechnology with significant long-term scaling potential.
Momentum investorMixed fitStock momentum is conditional on positive clinical trial readouts, partnership milestone announcements, and broader speculative biotech sector trends.
Value investorWeak fitThe company operates at substantial net losses without commercial product earnings or traditional value-metric support.
Dividend investorWeak fitRecursion pays no dividends, reinvesting all capital into research, clinical trials, and platform expansion.
Low-risk investorWeak fitHigh clinical trial attrition risks, price volatility, and lack of commercial cash flow expose investors to significant capital risk.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotech stocks frequently experience sharp price swings reacting to clinical data updates and market sentiment.
Valuation riskMedium / highValuations rely heavily on long-term discounted cash flow expectations for unproven AI discovery pipelines.
Competition risk (AI drug discovery competition)Medium / highThe rapid proliferation of alternative computational biology platforms and tech giants creates continuous pressure to maintain technological leadership.
Business qualityMediumWhile the platform infrastructure and partnerships are robust, the business model lacks commercial product validation.
Dividend incomeLow / noneNo dividend is distributed, making it entirely unsuitable for income-focused strategies.
Execution riskHighSuccessfully translating AI-driven biological insights into approved commercial drugs involves navigating complex and uncertain clinical trials.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.99B USD
Price to earnings Ratio -
1Y Target Price 7.32
Price to earnings Ratio -
1Y Target Price 7.32
Volume (30-day avg) 26.0M shares
Beta 1.15
52 Weeks Range 2.77 - 5.24
Updated Date 11/15/2026
52 Weeks Range 2.77 - 5.24
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.86

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
63.9%
Active BUY / eligible
69 / 108
30-Day BUY Count Change
+31
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
47.5%
Active BUY / eligible
19 / 40
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit -55.33%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
RXRX receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
RXRX has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid revenue growth (+26.9%) is partially offset by negative earnings growth (-39.1%), weak cash generation (FCF margin -506.5%), weak profitability (net margin -863.4%).

Financial Health Rating

★★★★★
RXRX's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 45.1%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is RXRX's strongest growth driver at +26.9% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-39.1%, negative) and free-cash-flow growth (-1.5%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 63.0% and approximately 97.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.53% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 8.07%
ARK Investment Management LLC 6.63%
State Street Corp 5.57%
Vanguard Portfolio Management, LLC 4.99%
Vanguard Capital Management, LLC 3.65%

Unit Economics (Per $1K Revenue)

★★★★★
RXRX generates approximately $-620 of gross profit, $-8,679 of operating income, and $-5,065 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.02%

Quantitative Style Profile

★★★★★
RXRX has a liquid profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Collaborations and PartnershipsUpfront payments, research funding, and development milestone fees from major pharmaceutical collaborators like Roche, Genentech, and Sanofi.Revenue is currently event-driven and lumpy, depending on successfully achieving scientific milestones with major pharma partners rather than recurring commercial drug sales.
Geographic Operations (United States & United Kingdom)Research and operational activities spanning North America and Europe, augmented by the integration of Exscientia's UK operations.Global footprint enables access to diverse international scientific talent and cross-border regulatory frameworks.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.52B
Price to Sales(TTM) 29.1
Enterprise Value 1.52B
Price to Sales(TTM) 29.1
Enterprise Value to Revenue 22.74
Enterprise Value to EBITDA -5.31
Shares Outstanding 622.76M
Shares Floating 606.87M
Shares Outstanding 622.76M
Shares Floating 606.87M
Percent Insiders 2.53
Percent Institutions 62.98

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.